Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2118-2124

  Schwartsmann, G ^a   Sprinz, E ^a   Kromfield, M ^a   Kalakun, L ^a   Sander, E ^a   Prolla, G ^a   Di Leone, L ^a   Gerhardt, L ^a   Mans, D R ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ETOPOSIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; KAPOSI SARCOMA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

EID: 0030903587     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2118     Document Type: Article

References (30)

1. Friedman-Kien AE, Saltzman BR: Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol 22:1237-1250, 1990
2. Levine AM: AIDS-related malignancies: The emerging epidemic. J Natl Cancer Inst 85:1382-1397, 1993
3. Karp JE, Groopman JE, Broder S: Cancer in AIDS, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 2093-2110
4. Yang JC, Rosenberg SA, Glatstein EJ, et al: Sarcomas of soft tissues, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 1436-1488
5. Lassoued K, Clauvel JP, Katlama C, et al: Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 66:1869-1872, 1990
6. Volberding PA, Abrams DI, Conant M, et al: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103:335-338, 1985
7. Lauberstein LJ, Kriegel RL, Odajynk CM, et al: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, vinblastine and bleomycin. J Clin Oncol 2:1115-1120, 1984
8. Gill PS, Rarick MU, McCutchan JA, et al: A systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 90:427-433, 1991
9. Bogner JR, Kronawitter U, Rolinski B, et al: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. J Acq Immune Defic Synd Hum Retrovirol 7:463-468, 1994
10. Saville MVV, Lietzau J, Pluda M, et al: Activity of paclitaxel (Taxol) as therapy for HIV-associated KS. Proc Am Assoc Cancer Res 14:A826, 1995 (abstr)
11. Fischl MA, Finkelstein BM, He W, et al: A phase II study of recombinant human alpha 2a and zidovudine in patients with AIDS-related KS: AIDS Clinical Trials Group. J Acq Immune Defic Synd Hum Retrovirol 11:379-384, 1996
12. Schwartsmann G, Sander E, Prolla G, et al: Phase II trial of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma (KS). Tumori 82:360-363, 1996
13. Schwartsmann G, Sprinz E, Kronfeld M, et al: A phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. Eur J Cancer 27:1637-1639, 1991
14. Sander E, Zampese M, Prolla G, et al: Phase II trial of low-dose, oral etoposide in AIDS-related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 12:54, 1993 (abstr)
15. Slevin ML, Clark PI, Joel SP: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
16. Slevin ML: Low-dose oral etoposide: A new role for an old drug? J Clin Oncol 8:1607-1609, 1990
17. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
18. Clark PI, Joel SP, Slevin ML: A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small-cell lung cancer. Proc Am Soc Clin Oncol 8:257, 1989 (abstr)
19. Paredes J, Kahn JO, Tong WP, et al: Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: A phase I multicenter trial of the AIDS Clinical Trials Group. J Acq Immune Defic Hum Retrovirol 9:138-144, 1995
20. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-349, 1961
21. Kriegel R, Laubenstein LJ, Muggia F: Kaposi's sarcoma: A new classification. Cancer Treat Rep 67:531-534, 1983
22. Schwartsmann G, Wanders J, Koier IJ, et al: EORTC New Drug Development Office coordinating and monitoring program for phase I and II trials with new anticancer agents. Eur J Cancer 9:1162-1168, 1991
23. Smyth RD, Pfeffer M, Scalzo A, et al: Bioavailability and pharmacokinetics of VP-16. Semin Oncol 12:48-56, 1985
24. Stewart DJ, Nundy D, Maroun JA, et al: Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69:269-273, 1985
25. Hande KR, Bennett R, Krozley MG, et al: Improved bioavailability (BA) with low-dose oral (po) etoposide (E). Proc Am Soc Clin Oncol 10:254, 1991 (abstr)
26. Strife RJ, Jardine I: Analysis of the anticancer drugs VP-16-213 and VM-26 and their metabolites by high performance liquid chromatography. J Chromatogr 182:211-220, 1980
27. Krown SE, Metroka C, Wernz J: Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response and staging criteria. J Clin Oncol 7:1201-1207, 1989
28. Krown SE, Testa M, Huang J: Validation of the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi's sarcoma. Proc Am Soc Clin Oncol 15:303, 1996 (abstr)
29. Einhorn LH: Daily oral etoposide in the treatment of cancer. Semin Oncol 18:43-47, 1990 (suppl 2)
30. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Oncol 26:818-821, 1990